® cephacare clavubactin ® trimacare® amoxycare ® ® marbocare ® prednicare fungiconazol ® ketoconazole fungiconazol ® - the only veterinary licensed antifungal tablet for dogs • Hypoallergenic chicken flavour - suitable for dogs with atopic dermatitis or food allergies 11 • Easy to administer - single daily dose • Affordable antifungal 4-way split SmartTabs ® give dosing accuracy to match the weight of animal 1 X 400mg per 40kg 1 X 200mg per 20kg 11. Verlinden A. et al., Food allergy in dogs and cats: a review, Critical Reviews in Food Science and Nutrition (2006) 46, 259-273. Dosage 10mg/kg bodyweight once daily
cephacare ® Cephacare flavour tablets for cats and dogs: Contraindications, warnings etc: Do not use in cases of known hypersensitivity to the active substance, to other cephalosporins, to other substances of the beta-lactam group or to any of the excipients. Do not use in rabbits, gerbils, guinea pigs and hamsters. Transient episodes of soft faeces and vomiting have been observed in cats when given products containing cefalexin. Treatment should be discontinued if vomiting and diarrhoea develop. Vomiting has been observed occasionally in dogs when given products containing cefalexin. Use of the product should be based on susceptibility testing and take into account official and local antimicrobial policies. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to cefalexin and may decrease the effectiveness of treatment with penicillins, due to the potential for cross resistance. In the case of an allergic reaction, treatment should be withdrawn. The administration of cefalexin has been shown to produce no serious side-effects at many times the recommended dose rate. As with other antibiotics which are excreted mainly by the kidneys, unnecessary accumulation may occur in the body when renal function is impaired. In cases of known renal insufficiency the dose should be reduced, antimicrobials known to be nephrotoxic should not be administered concurrently and the product should be used only according to a risk/benefit assessment by the responsible veterinarian. Interaction with other medicinal products and other forms of interaction: The bactericidal activity of cephalosporins is reduced by concomitant administration of bacteriostatic acting compounds (macrolides, sulphonamides and tetracyclines). Nephrotoxicity can be increased when 1st generation cephalosporins are combined with polypeptide antibiotics, aminoglycosides and some diuretics (furosemide). Concomitant use with such active substances should be avoided. The safety of the product has not been demonstrated in studies in pregnant or lactating dogs and cats. Use only in accordance with a risk/benefit assessment by the responsible veterinarian. Marketing authorisation numbers: UK: 50mg Vm10347/4025, 250mg Vm 10347/4026, 500mg Vm 10347/4027. IE: 50mg VPA 10778/002/001, 250mg VPA 10778/002/002, 500mg VPA 10778/002/003. Legal category: UK: . IE: POM. Please see Summary of Product Characteristics (SPC) for full details. clavubactin ® Clavubactin tablets for cats and dogs: Contraindications: Do not use in animals with known hypersensitivity to penicillin or other substances of the beta-lactam group. Do not use in serious dysfunction of the kidneys accompanied by anuria and oliguria. Do not use in rabbits, guinea pigs, hamsters, chincillas or gerbils. Do not use in case of known resistance to the combination. Special warnings: None known. Special precautions for use: Official, national and regional antimicrobial policies with respect to the use of broad-spectrum antibiotics should be taken into account. Do not use in case of bacteria sensitive to narrow spectrum penicillins or to amoxicillin as single substance. It is advised that upon initiating therapy appropriate sensitivity testing is performed and that therapy is continued only after susceptibility to the combination has been established. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the amoxicillin/clavulanate, and may decrease the effectiveness of treatment with β-lactam antibiotics. In animals with hepatic and renal failure, the dosing regimen should be carefully evaluated. Caution is advised in the use in small herbivores. Adverse reactions: Mild gastrointestinal symptoms (diarrhoea, nausea and vomiting) may occur after administration of the product. Allergic reactions (skin reactions, anaphylaxia) may occasionally occur. In these cases, administration should be discontinued and a symptomatic treatment given. Use during pregnancy, lactation or lay: Laboratory studies in rats and mice have not produced any evidence of teratogenic or fetotoxic effects. No studies have been conducted in the pregnant and lactating dogs. Use only according to the benefit/risk assessment by the responsible veterinarian. Interaction with other medicinal products and other forms of interaction: Chloramphenicol, macrolides, sulfonamides, and tetracyclines may inhibit the antibacterial effects of penicillins.The potential for allergic cross-reactivity with other penicillins should be considered. Penicillins may increase the effect of aminoglycosides. Overdose Mild gastrointestinal symptoms (diarrhea, nausea and vomiting) may occur more frequently after overdose of the product. Marketing authorisation numbers: UK: 50/12.5mg Vm 19994/4028, 250/62.5mg Vm 19994/4026, 500/125mg Vm 19994/4027. IE: 50/12.5mg VPA 10475/014/001, 250/62.5mg 10475/014/002, 500/125mg VPA 10475/014/003. Legal category: UK: . IE: POM. Please see Summary of Product Characteristics (SPC) for full details. trimacare ® Trimacare tablets for dogs and adult cats: Contra-indications: Not suitable for use in cats. Special warnings for each target species: None. Special precautions for use: Maintain adequate fluid intake during treatment. Not to be used in cases of hepatic renal impairment or blood dyscrasia. Wherever possible, use of Trimacare should be based on susceptibility testing. Special precautions to be taken by the person administering the veterinary medicinal product to animals. Take care to avoid skin contact. Wash hands after use. Sulphonamides may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to sulphonamides may lead to cross reactions with other antibiotics. Allergic reactions to these substances may occasionally be serious. Do not handle this product if you are sensitive to sulphonamides. If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the doctor this warning. Adverse reactions: A low incidence of polyarthropathy and Keratoconjunctivitis Sicca (Dry Eye) has been reported in dogs following oral administration of potentiated sulphonamides. If either of these conditions occurs, it is recommended that medication is stopped and that future treatment with similar products is avoided. Sulphonamide sensitivity is rare in companion animals but should be considered in cases of unexpected responses to treatment. Use during pregnancy, lactation or lay: Can be safely administered during pregnancy and lactation. Interaction with other medicinal products and other forms of interaction: None known. Marketing Authorization Number: Vm:02000/4147. Legal category: . Please see Summary of Product Characteristics (SPC) for full details. marbocare ® Marbocare flavour tablets for cats and dogs: Contraindications: Do not use in dogs aged less than 12 months, or less than 18 months for exceptionally large breeds of dogs, such as Great Danes, Briard, Bernese, Bouvier and Mastiffs, with a longer growth period. Not recommended for use in cats aged less than 16 weeks. Do not use in animals with known hypersensitivity to marbofloxacin or other (fluoro)quinolones or to any of the excipients. Do not use in case of confirmed or suspected resistance to fluoroquinolones (cross resistance). Adverse reactions: Mild side effects such as vomiting, softening of faeces, modification of thirst or transient increase in activity may occasionally occur. These signs cease spontaneously after treatment and do not necessitate cessation of treatment. Special warnings: The fluoroquinolones have been shown to induce erosion of articular cartilage in juvenile dogs and care should be taken to dose accurately especially in young animals. However at the therapeutic recommended dosage, no severe side-effects are to be expected in dogs and cats. Some fluoroquinolones at high doses may have an epileptogenic potential. Cautious use is recommended in dogs and cats diagnosed as suffering from epilepsy. A low urinary pH could have an inhibitory effect on the activity of marbofloxacin. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly to other classes of antimicrobials. Whenever possible, use of fluoroquinolones should be based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the (fluoro)quinolones and may decrease effectiveness of treatment with other quinolones due to the potential for cross-resistance. Use during pregnancy and lactation: Studies in laboratory animals (rats, rabbits) showed no teratogenicity, embryotoxicity and maternotoxicity with marbofloxacin at therapeutic doses. The safety of marbofloxacin has not been assessed in pregnant and lactating dogs. Use only accordingly to the benefit/risk assessment by the responsible veterinarian in pregnant and lactating animals. Marketing authorisation numbers: UK: 5mg Vm 34534/4003, 20mg Vm 34534/4004, 80mg 34534/4005. IE: 5mg 10534/4/1, 20mg 10534/4/2, 80mg 10534/4/3. Legal category: UK: . IE: POM. Please see Summary of Product Characteristics (SPC) for full details. amoxycare ® Amoxycare 200mg tablets: Contra-indications: Should not be given to penicillin sensitive animals. As with other penicillins, amoxicillin should not be used orally or parenterally in rabbits, guinea pigs, hamsters or gerbils. Caution is advised when used in other very small herbivores. Special precautions: Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local epidemiological information. Marketing authorisation number: Vm 02000/4143. Legal category: . Amoxycare 250mg hard capsules: Contra-indications: Not to be administered to animals known to be sensitive to beta-lactam antibiotics. Do not treat dogs less than 10kg bodyweight. Not to be administered to small herbivores. Special warnings: As with all penicillins, the product may cause hypersensitivity (allergy) following ingestion. It should not be used when the dog is known to be allergic to penicillins. As with all other penicillins, bacterial resistance to amoxicillin may occur. Thus antibiotic sensitivity testing should be considered if a clinical condition fails to respond to treatment within 5 days. In common with many antibiotics, administration of amoxicillin may disturb the gut flora. Special precautions for use: For oral administration only. Marketing authorisation number: Vm 12597/4036. Legal category: . Amoxycare Palatable Drops: Each bottle contains the equivalent of 750mg amoxicillin as amoxicillin trihydrate and when reconstituted with 12ml water gives a 15ml suspension containing amoxicillin at a concentration of 50mg/ml. Contra-indications: Not to be used in animals known to be hypersensitive to penicillin. Not to be used orally or parenterally in rabbits, guinea pigs, hamsters or gerbils. Caution is advised when used in any other small herbivores. Undesirable Effects: No known undesirable effects. Marketing authorisation number: Vm 02000/4157. Legal category: . Special precautions for all of the above amoxicillin products: Care should be taken to avoid accidental self-injection. In the case of accidental self-injection, seek medical advice immediately. Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious. Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations. Handle this product with great care to avoid exposure taking all recommended precautions. If you develop symptoms following exposure, such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty breathing are more serious symptoms and require urgent medical attention. Wash hands after use. Adverse reactions: Occasional local tissue reaction may result from use of this product. Can be safely administered during pregnancy and lactation. It is not generally recommended to use bactericidal and bacteriostatic antibiotics at the same time. Please see Summary of Product Characteristics (SPC) for full details. prednicare ® Prednicare tablets for cats and dogs: Contraindications: Systemic corticosteroid therapy is generally contra-indicated in patients with renal disease or diabetes mellitus. Administration is contra-indicated where corneal ulceration is present. The use of corticosteroids may render vaccinations inoperative. Administration in late pregnancy may cause early parturition and abortion. Special precautions for use: (i) Caution is necessary when prescribing corticosteroids in animals with the following conditions: epilepsy, glaucoma, hypertension, osteoporosis, peptic ulceration and previous steroid myopathy. (ii) Impermeable gloves should be worn whilst administering the product. Wash hands thoroughly with soap and water after handling this product. In case of accidental ingestion, drink plenty of water and seek medical advice. Adverse reactions: Anti-inflammatory steroids, such as prednisolone, are known to exert a wide range of side-effects. Whilst single high doses are generally well tolerated, they may induce severe side-effects in long-term use. Dosage in medium to long term should therefore generally be kept to the minimum necessary to control symptoms. Steroids themselves, during treatment, may cause Cushingoid symptoms – refer to the SPC for further information. Systemically acting corticosteroids may cause polyuria, polydipsia and polyphagia, particularly during the early stages of therapy. Some corticosteroids may cause sodium and water retention and hypokalaemia in long term use. Systemic corticosteroids have caused deposition of calcium in the skin (calcinosis cutis). Corticosteroids are not recommended for use in pregnant animals. Administration in early pregnancy is known to have caused foetal abnormalities in laboratory animals. Administration in late pregnancy may cause early parturition or abortion. Corticosteroids may delay wound healing and the immunosuppressant actions may weaken resistance to or exacerbate existing infections. In the presence of bacterial infection, anti-bacterial drug cover is usually required when steroids are used. In the presence of viral infections, steroids may worsen or hasten the progress of the disease. Gastrointestinal ulceration has been reported in animals treated with corticosteroids and G.I.T. ulceration may be exacerbated by steroids in patients given non-steroidal anti-inflammatory drugs and in corticosteroid treated animals with spinal cord trauma. Steroids may cause enlargement of the liver (hepatomegaly) with increased serum hepatic enzymes. Use during pregnancy, lactation or lay: Corticosteroids are not recommended for use in pregnant animals. Administration in early pregnancy is known to have caused foetal abnormalities in laboratory animals. Administration in late pregnancy may cause early parturition or abortion. Interaction with other medicinal products and other forms of interaction: The use of corticosteroids may render concurrent vaccinations inoperative. Corticosteroid treated animals may succumb to infection if concurrently vaccinated with live vaccines. Gastro-intestinal tract ulceration may be exacerbated by steroids in patients given non-steroidal anti-inflammatory drugs and in corticosteroid treated animals with spinal cord trauma. Serum levels of concurrently administered salicylates may increase considerably on withdrawal of corticosteroid therapy, with the potential for toxic effects and/or increased gastro-intestinal tract ulceration. Steroids may cause enlargement of the liver (hepatomegaly) with increased serum hepatic enzymes. The effectiveness of anticoagulants may be modified by concurrent corticosteroid therapy. The actions of hypoglycaemic agents will be antagonised by the hyperglycaemic effects of corticosteroids. Hypokalaemia may occur when amphotericin and corticosteroids are used concurrently. The simultaneous use of corticosteroids and methotrexate may increase methotrexate toxicity. The therapeutic effects of some barbiturates, phenytoin, and rifampicin may be reduced by the concurrent use of corticosteroids. Marketing authorisation numbers: 1mg Vm 10347/4018, 5mg Vm 10347/4017. Legal category: . Please see Summary of Product Characteristics (SPC) for full details. fungiconazol ® Fungiconazol tablets for dogs: Contraindications: Do not administer to animals with liver failure. Do not administer to animals with known hypersensitivity to the active substance or to any of the excipients. Special warnings for each target species: Treatment with ketoconazole suppresses testosterone concentrations and increases progesterone concentrations and may affect breeding effectiveness in male dogs during and for some weeks after treatment. Although rare, repeated use of ketoconazole may induce cross-resistance to other azoles. Special precautions for use: Treatment of dermatophytosis should not be limited to treatment of the infected animal(s). It should also include disinfection of the environment, since spores can survive in the environment for long periods of time. Other measures such as frequent vacuuming, disinfection of grooming equipment and removal of all potentially contaminated material that cannot be disinfected will minimize the risk of re-infection or spread of infection. Combination of systemic and topical treatment is recommended. In case of long term treatment administration, liver function should be closely monitored. If clinical signs suggestive of liver dysfunction develop, treatment should be discontinued immediately. Adverse reactions: In rare cases, neurological symptoms (apathy, ataxia, tremors), hepatic toxicity, vomiting, anorexia and/or diarrhoea may be observed at standard doses. Ketoconazole has anti-androgen and anti-glucocorticoid effects; it inhibits the conversion of cholesterol to steroid hormones such as testosterone and cortisol in a dose dependent and time-dependent manner. Use during pregnancy, lactation or breeding: Studies in laboratory animals have shown evidence of teratogenic and embryotoxic effects. The safety of the product has not been established in pregnant or lactating bitches. Use is not recommended during pregnancy. Interaction with other medicinal products and other forms of interaction: Do not administer with antacids and/or H2-receptor antagonists (cimetidine/rantidine) or proton pump inhibitors (e.g. omeprazole) as the absorption of ketoconazole may be modified (absorption requires an acid environment). Ketoconazole is a substrate and potent inhibitor of cytochrome P450 3A4 (CYP3A4). It may decrease the elimination of drugs metabolized by CYP3A4, thereby altering their plasma concentrations. Inducers of cytochrome P450 may increase the rate of metabolism of ketoconazole. Relevant veterinary interactions include cyclosporines, macrocyclic lactones (ivermectin, selamectin, milbemycin), midazolam, cisapride, amlodipine, fentanyl, macrolides (clarithromycin erythromycin), digoxin, anticoagulants and phenobarbital. Ketoconazole inhibits the conversion of cholesterol to cortisol and may thus affect trilostane/mitotane dosing in dogs concurrently being treated for hyperadrenocorticism. Marketing authorisation numbers: UK: 200mg Vm 41821/4012, 400mg Vm 4182/4013. IE: 200mg VPA 10475/012/001, 400mg VPA 10475/012/002. Legal category: UK: . IE: POM. Please see Summary of Product Characteristics (SPC) for full details.
Change language